Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

The company also reaffirmed its guidance for the remainder of the year, emphasizing its strategic focus on research and development along with operational efficiencies. Pfizer reported revenues of $13 ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational relationships; ...

however Pfizer noted in its earnings release that the guidance "does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict ...

NEW YORK – Amid questions over the financial impact of tariffs and Medicare Part D reform, Pfizer did not meet the consensus Wall Street revenue expectations in the first quarter of 2025 but saw ...

Pfizer Inc. PFE will release earnings results ... Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate ...

Pharmaceutical companies have stepped up pressure on the Government to push back against proposed new regulations of the sector, which pharma giant Pfizer privately warned could damage the Irish ...